Sygnature Discovery has Chosen Elsevier as New Preferred Partner to Empower its Global Team of Chemists

Sygnature Discovery is pleased to announce its new partner Elsevier, a global information and analytics company. More than 400 Sygnature chemists based in North America and the UK now have access to Elsevier’s cutting-edge chemistry platform, Reaxys,

This collaboration is a significant milestone in Sygnature’s ongoing efforts to enhance its scientific capabilities and streamline its workflows. By integrating Reaxys, Sygnature provides its scientists with a powerful, unified platform designed to support reaction chemistry, synthesis, and innovation in drug discovery. As Reaxys is renowned for its extensive and growing database of reaction chemistry, it also delivers a best-in-class retrosynthesis technology that harnesses the power of artificial intelligence (AI).

“As AI continues to shape the future of scientific research, we are confident that Reaxys offers the most advanced retrosynthesis technology available,” said Colin Sambrook Smith, Sygnature Discovery’s Director of Computational Sciences and Informatics.

“This partnership will allow our scientists to access a wealth of chemistry data and insights, significantly accelerating our research and enabling us to better serve our clients.”

Beyond the technological benefits, the smooth integration of Reaxys across Sygnature’s global teams is crucial for success. Comprehensive onboarding provided by Reaxys – which includes ongoing training for over 400 chemists – is ensuring that the transition from legacy systems is seamless and that the platform’s full capabilities are leveraged from day one.

“Partnering with Elsevier is not just about adopting a new tool, it’s enhancing how we work. The success of this partnership is based upon a robust onboarding process so our scientists can quickly unlock Reaxys’s potential,” added Sambrook Smith.

As Sygnature Discovery continues to push the boundaries of scientific innovation, the integration of Reaxys will provide the foundation for more efficient workflows, accelerated timelines, and deeper insights into chemical reactions and compound data, further solidifying Sygnature’s position as a leader in the drug discovery industry.

About Sygnature Discovery

Sygnature Discovery is a world-leading integrated drug discovery contract research organization based in the UK and Canada with headquarters in Nottingham (UK). Additional sites are located in Alderley Park, Macclesfield, and Glasgow (UK), as well as Montreal and Quebec City (Canada). Its team of over 1,000 employees, which includes 900 scientists, partners with global pharma, biotech, and NFP organizations. Since 2011, Sygnature Discovery has delivered over 40 novel pre-clinical and 25 clinical compounds, with its scientists named on over 170 patents. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more.

About Reaxys

Reaxys is a chemistry research and education solution from Elsevier providing chemical substance, properties, reaction and medicinal chemistry information for both bench chemistry and machine learning methods used in drug discovery and chemical/pharmaceutical R&D. Reaxys provides the most comprehensive manually extracted and curated chemistry and bioactivity database covering over 1 billion published experimental facts including 280 million organic, inorganic and organometallic compounds, 74 million chemical reactions, 46 million bioactivities from over 110 million documents including patents and journals. 

About Elsevier

Elsevier is a global leader in scientific information and analytics, assisting researchers and healthcare professionals in advancing science and enhancing health outcomes. With over 140 years of experience, our 9,500 employees worldwide, including 2,500 technologists, provide support to various stakeholders in research, healthcare, and education. Offering 2,900 scientific journals and reference books, such as Cell Press and The Lancet, we leverage trusted content and innovative AI-driven technologies. Through collaborations with the Elsevier Foundation, we promote diversity and inclusion in the global scientific community. As part of RELX, we offer information-based analytics and decision tools for professionals worldwide. Learn more at www.elsevier.com.